GU Cancers Symposium

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.

In both racial cohorts, median MFS was not reached in the darolutamide group.

“Looking at our overall results, not surprisingly, we can show a clear benefit of ARPIs on overall survival," says David Fisher, MSc, MA.

The investigators reported an HR for OS of 0.796 (95% CI, 0.661-0.958; 2-sided P = .0155) for talazoparib/enzalutamide vs enzalutamide/placebo.

The treatment combination was associated with median radiographic progression-free survival of 14.3 months vs 6.2 months with enzalutamide alone.

“At this time, we should offer similar treatment to both African American and Caucasian patients,” says Jasmeet Kaur, MD.

“The response rate now with the updated dataset has gone up to just about 50% across the cohort,” says Martin H. Voss, MD.

"We could have had our expansion doses [at] 40 mg, but we made the clinical decision to go with 20 mg in expansion based on a hope for future clinical tolerability and longevity," says Jacqueline T. Brown, MD.

“The co-primary end points are safety and overall response rate as measured via RESIST v1.1,” says Jonathan A. Chatzkel, MD.

“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.

Data revealed that 49% of prostate cancer signups in clinical trials were among patients newly diagnosed with cancer, compared with 32% among patients with other solid tumors.

“Medical oncologists, including academic and in the community, tend to order more genomic testing than urologic oncologists,” says Dalia Kaakour, MD, MS, MPH.

"I think it's very interesting to see that we continue to see a survival benefit at 55-months follow-up," says Maria Teresa Bourlon, MD, MSc, MS.

“It's important to note as well that the kidney cancer biology is really distinct from a lot of other solid tumors, and particularly other immunotherapy response to solid tumors,” says David A. Braun, MD, PhD.

“If you put everything together, the cabo/atezo combination statistically significantly improved the progression-free survival and reduced the risk of progression or death by 35% in a patient population with very poor prognosis,” says Neeraj Agarwal, MD, FACSO.

“Our study provides real-world recurrence and survival rates, [however], a major limitation is the retrospective nature of the analysis,” wrote the investigators, led by Viktor Gruenwald, MD, PhD.

“This will become a very attractive option if approved by the FDA because the treatment burden on patients will be significantly reduced, thus making it easier for patients to access it,” says Saby George, MD, FACP.

"When we think about germline mutations, I think the number one thing that comes through for many urologists as well as oncologists is Lynch syndrome," says Laura Bukavina, MD, MPH, MSc.

Patients in the subcutaneous arm (n = 242) achieved a geometric mean Cavgd28 of 77.373μl/mL (90% CI, 74.555-80.297) compared with 36.875 μl/mL (90% CI, 35.565-38.235) in the IV arm (n = 245), for a geometric mean ratio of 2.098 μl/mL (90% CI, 2.001-2.200).

Overall, the pathological complete response rate among patients who received APL-1202 plus tislelizumab was 39%, compared with 21% among those who received tislelizumab alone.

“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.

“[It is] reassuring that in patients who had a prior novel hormonal agent, the combination of enzalutamide plus talazoparib is still effective [and] still an effective option,” says Arun Azad, MD.

"[This is] the first time ever since we started conducting randomized phase 3 studies in the adjuvant setting of kidney cancer that we see an overall survival benefit," says Toni K. Choueiri, MD.

Patient subgroups that favored nivolumab vs placebo included patients with sarcomatoid features (HR, 0.42; 95% CI, 0.17-1.07), PD-L1 expression of 1% or greater (HR, 0.53; 95% CI, 0.22-1.29), and those with lower limit of normal hemoglobin at baseline (HR, 0.49; 95% CI, 0.25-1.49).

“The benefit of enfortumab vedotin plus pembrolizumab in all prespecified subgroups was consistent with the overall patient population,” said Michiel S. Van Der Heijden, MD, PhD.

Belzutifan extended the time to disease progression and was associated with improvements in QoL scores compared with everolimus.

Adjuvant pembrolizumab prolonged overall survival versus placebo in certain patients with clear cell renal cell carcinoma.

Adjuvant pembrolizumab reduced the risk of disease recurrence or death, but did not improve overall survival, compared with observation in patients with urothelial carcinoma.

Results from the phase 2 PemCab trial showed that the first-line combination elicited promising antitumor activity with tolerable toxicity in patients with advanced urothelial carcinoma, including those who were cisplatin ineligible.

Andrea B. Apolo, MD, shares key interim findings from the AMBASSADOR Alliance trial.